| scholarly article | Q13442814 |
| P2093 | author name string | Bruno Reichart | |
| Bruno Meiser | |||
| Ingo Kaczmarek | |||
| Peter Uberfuhr | |||
| Ioannis Adamidis | |||
| P2860 | cites work | Chronic renal failure after transplantation of a nonrenal organ | Q28204928 |
| A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus | Q28374686 | ||
| Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management | Q33332820 | ||
| Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study | Q33349178 | ||
| Mycophenolate mofetil and its mechanisms of action | Q33957177 | ||
| Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients | Q33968031 | ||
| Reducing adverse effects of immunosuppressive agents in kidney transplant recipients | Q34547749 | ||
| Cyclosporine-associated end-stage nephropathy after cardiac transplantation: incidence and progression | Q41389928 | ||
| Tacrolimus or cyclosporine: which is the better partner for mycophenolate mofetil in heart transplant recipients? | Q42636782 | ||
| Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure | Q44845167 | ||
| A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. | Q46186465 | ||
| P433 | issue | 4 Pt 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunosuppression | Q1455316 |
| P304 | page(s) | 827-831 | |
| P577 | publication date | 2005-04-01 | |
| P1433 | published in | American Journal of Transplantation | Q4744273 |
| P1476 | title | First experience with de novo calcineurin-inhibitor-free immunosuppression following cardiac transplantation | |
| P478 | volume | 5 |
| Q26738510 | A Proposal for Early Dosing Regimens in Heart Transplant Patients Receiving Thymoglobulin and Calcineurin Inhibition |
| Q36491797 | Acute rejection after heart transplantation. |
| Q37064446 | Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. |
| Q46147919 | Chronic kidney disease after heart transplantation. |
| Q38240994 | Chronic renal insufficiency in heart transplant recipients: risk factors and management options |
| Q51805179 | Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients. |
| Q36525284 | Heart and lung transplantation in children |
| Q37740452 | Impact of different long-term maintenance immunosuppressive therapy strategies on patients' outcome after heart transplantation |
| Q26999269 | Induction therapy in heart transplantation: where are we now? |
| Q40281019 | Inhibition of restenosis development after mechanical injury: a new field of application for malononitrilamides? |
| Q46310697 | Minimization of immunosuppression: transplant immunology |
| Q58639737 | Sirolimus and FK778: a comparison of two anti-proliferative immunosuppressants for prevention of experimental obliterative airway disease |
| Q79348778 | Sirolimus experience in heart transplantation |
| Q46915319 | Sirolimus in de novo heart transplant recipients with severe renal impairment |
| Q37854845 | Surgical wound complications after heart transplantation |
| Q36577612 | The challenge of renal function in heart transplant children |
| Q35175413 | Thymoglobulin induction in heart transplantation: patient selection and implications for maintenance immunosuppression. |
| Q36655174 | Treatment of allograft vasculopathy in heart transplantation |
| Q36750090 | Use of sirolimus in solid organ transplantation |
| Q45992631 | Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients. |
| Q82770352 | [Review of clinical trials on minimization and interruption of calcineurin inhibitors (CNIs) and protocols without CNIs in the transplantation of different organs (kidney, heart, and liver)] |
Search more.